TG Therapeutics (TGTX) Set to Announce Quarterly Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is preparing to announce its earnings results before the market opens on Monday, November 4th. Analysts are anticipating that the company will report earnings of $0.04 per share for the quarter.

The last time TG Therapeutics released its quarterly earnings data was on August 6th. During that reporting period, the biopharmaceutical company achieved a surprising earnings per share (EPS) of $0.04, exceeding the consensus estimate of ($0.04) by $0.08. The company recorded a return on equity of 57.73% and had a net margin of 27.60%. In terms of revenue, TG Therapeutics reported $73.47 million for the quarter, which was higher than the analyst estimates of $65.92 million. This marked a significant increase of 357.0% compared to the same quarter of the previous year, during which the company had a loss of ($0.34) EPS.

Price Performance of TG Therapeutics

As of Friday, shares of TG Therapeutics were trading at $26.90. The company possesses a market capitalization of $4.16 billion, with a price-to-earnings ratio of 44.10 and a beta of 2.21. The current financial metrics indicate a debt-to-equity ratio of 0.58, a current ratio of 3.58, and a quick ratio of 2.83. Over the last year, the stock has fluctuated between a low of $9.81 and a high of $26.99. The company's 50-day and 200-day moving averages stand at $23.51 and $20.01, respectively.

Analyst Opinions on TG Therapeutics

Several equity research analysts have shared their insights on TG Therapeutics' stock. For instance, the Goldman Sachs Group raised its price target from $18.00 to $20.00 and set a "neutral" rating for the stock on August 7th. TD Cowen also commenced coverage of TG Therapeutics, issuing a "buy" rating coupled with a $50.00 price target. Meanwhile, HC Wainwright reiterated a "buy" rating and established a price target of $49.00 on September 18th. Additionally, B. Riley increased their price objective from $29.00 to $34.00, maintaining a "buy" rating. Currently, two analysts recommend holding the stock, while five suggest buying, giving TG Therapeutics a consensus rating of "Moderate Buy" and an average price target of $36.33.

Overview of TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical entity focused on the research, development, and commercialization of innovative therapies aimed at treating B-cell mediated diseases. The company markets BRIUMVI, an anti-CD20 monoclonal antibody used for managing adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

TG, Therapeutics, Earnings